ABBV monthly performance report
Monthly ABBV research: returns, drawdown, relative strength, seasonality, and key stats.
ABBV monthly report
—
Key takeaways
- AbbVie (ABBV) closed September 2026 at $256.46, up 0.02% for the month and +20.40% over the trailing 12 months.
- Year-to-date, ABBV is +12.24%, underperforming the S&P 500 which has returned +12.94% YTD.
- The stock is trading +12.36% versus its 200-day moving average ($228.24), a bullish technical signal.
- Over the past three years, ABBV has outperformed the S&P 500 by +2.35%, with a relative strength index reading of 102.4.
- Win rate over the trailing 39 months stands at 61.5% — 24 positive months versus 15 negative months.
AbbVie ended September 2026 at $256.46, posting a monthly return of +0.02%. The S&P 500 returned +0.41% over the same window, leaving relative performance at −0.39%.
The current quarter stands at +0.28% (Q3 2026 (QTD)), while medium-term trend remains constructive: price is +12.36% versus the 200-day moving average ($228.24).
Year-to-date, ABBV is +12.24% against SPY +12.94%, a gap of −0.70%. The stock is currently −4.12% below its 52-week high, with maximum 3-year drawdown at −21.46%.
| Period | ABBV | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | −2.01% | +0.66% | −2.67% |
| 1 Week | −2.45% | −0.12% | −2.33% |
| 1 Month | +0.02% | +0.41% | −0.39% |
| 3 Months | +19.06% | +2.11% | +16.95% |
| 6 Months | +9.48% | +13.21% | −3.73% |
| YTD | +12.24% | +12.94% | −0.70% |
| 12 Months | +20.40% | +18.65% | +1.75% |
| 3 Years | +73.05% | +70.70% | +2.35% |
| Rank | Month | Return |
|---|---|---|
| #1 | Jun 2026 | +16.90% |
| #2 | Feb 2025 | +14.11% |
| #3 | Jul 2023 | +11.63% |
| #4 | Aug 2025 | +10.78% |
| #5 | Sep 2025 | +10.18% |
| Rank | Month | Return |
|---|---|---|
| #1 | Apr 2024 | −10.58% |
| #2 | Nov 2024 | −10.49% |
| #3 | Apr 2025 | −7.32% |
| #4 | Mar 2026 | −6.92% |
| #5 | Oct 2025 | −6.68% |
| Quarter | Return |
|---|---|
| Q2 2025 | −10.63% |
| Q3 2025 | +24.71% |
| Q4 2025 | −1.37% |
| Q1 2026 | −6.33% |
| Q2 2026 | +16.73% |
| Q3 2026 (QTD) | +0.28% |
| Year | Return |
|---|---|
| 2023 | −0.29% |
| 2024 | +15.41% |
| 2025 | +28.84% |
| 2026 | +9.64% |
| Metric | Value |
|---|---|
| 52-Week High | $267.47 (2026-07-29) |
| 52-Week Low | $191.00 (2026-04-29) |
| Current Price | $256.46 |
| 200-Day Moving Average | $228.24 |
| Price vs 200DMA | +12.36% |
| 3-Year Maximum Drawdown | −21.46% (2025-04-21) |
| Current Drawdown from 52W High | −4.12% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 102.4 |
| 3-Year Excess Return vs S&P 500 | +2.35% |
| RS Peak | 118.8 (Mar 2025) |
| RS Trough | 84 (May 2026) |
| Status | Outperforming Benchmark |
Frequently asked questions
What was ABBV's return for this report period?
ABBV returned +0.02% in the latest monthly window ending 2026-09-04.
Has ABBV outperformed SPY year to date?
YTD ABBV: +12.24% vs SPY: +12.94%.
What is ABBV's 12-month return?
+20.40% over the trailing 12 months.
Is ABBV above or below its 200-day moving average?
Price is +12.36% versus 200DMA ($228.24).
What is the maximum drawdown in the 3-year window?
−21.46% on 2025-04-21.